Takashi Kenmochi

Prof. Dr. Takashi Kenmochi

Department of Organ Transplant Surgery, School of Medicine, Fujita Health University, Toyoake, Japan
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
UBUgo Boggi
Ugo Boggi
FVFabio Vistoli
Fabio Vistoli
AAAxel Andres
Axel Andres
HAHelmut P. Arbogast
Helmut P. Arbogast
LBLionel Badet
Lionel Badet
TBThierry Berney
Thierry Berney
The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic patients, and 110 experts’ recommendations for the practice of pancreas transplantation. The main message from this consensus conference is that both simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone can improve long-term patient survival, and all types of pancreas transplantation dramatically improve the quality of life of recipients. Pancreas transplantation may also improve the course of chronic complications of diabetes, depending on their severity. Therefore, the advantages of pancreas transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney transplantation increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Additionally, preemptive SPK, when compared to SPK performed in patients undergoing dialysis, appears to be associated with improved outcomes. Time on dialysis has negative prognostic implications in SPK recipients. Increased long-term survival, improvement in the course of diabetic complications, and amelioration of quality of life justify preferential allocation of kidney grafts to SPK recipients. Audience discussions and live voting are available online at the following URL address: http://mediaeventi.unipi.it/category/1st-world-consensus-conference-of-pancreas-transplantation/246.

1 January 2013 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
TITAIHEI ITO
TAIHEI ITO
DCDong Chen
Dong Chen
CCCheng-Wei Tom Chang
Cheng-Wei Tom Chang
TKTakashi Kenmochi
Takashi Kenmochi
TSTomonori Saito
Tomonori Saito
JTJon Y. Takemoto
Jon Y. Takemoto
The aims of this study were to produce mesobiliverdin IXα, an analog of anti-inflammatory biliverdin IXα and to test its ability to enhance rat pancreatic islet yield for allograft transplantation into diabetic recipients. Mesobiliverdin IXα was synthesized from phycocyanobilin derived from cyanobacteria, and its identity and purity were analyzed by chromatographic and spectroscopic methods. Mesobiliverdin IXα was a substrate for human NADPH biliverdin reductase. Excised Lewis rat pancreata infused with mesobiliverdin IXα and biliverdin IXα-HCl (1 – 100 μM) yielded islet equivalents as high as 86.7% and 36.5%, respectively, above those from non-treated controls, and the islets showed a high degree of viability based on dithizone staining. When transplanted into livers of streptozotocin-induced diabetic rats, islets from pancreata infused with mesobiliverdin IXα lowered non-fasting blood glucose levels in 55.6% of the recipients and in 22.2% of control recipients. In intravenous glucose tolerance tests, fasting blood glucose levels of 56 post-operative day recipients with islets from mesobiliverdin IXα infused pancreata were lower than those for controls and showed responses that indicate recovery of insulin-dependent function. In conclusion, mesobiliverdin IXα infusion of pancreata enhanced yields of functional islets capable of reversing insulin dysfunction in type 2 diabetic recipients. Since its production is scalable, mesobiliverdin IXα has clinical potential as a protectant of pancreatic islets for allograft transplantation.

Verified
Journal Article
Open access
PDF file
TITAIHEI ITO
TAIHEI ITO
TKTakashi Kenmochi
Takashi Kenmochi
NANaohiro Aida
Naohiro Aida
HMHajime Matsushima
Hajime Matsushima
KKKei Kurihara
Kei Kurihara
TIToshinori Ito
Toshinori Ito
Background: The impact of pancreas transplantation, including kidney transplantation on patients’ life prognoses, is unclear in Japan. An analysis of the data of the Japan Pancreas Transplant Registry was performed to compare the patient survival between on the waiting list and after pancreas transplantation, and investigate the factors that affect the patient survival after pancreatic transplantation. Methods: The life prognoses of 361 patients who underwent pancreas transplantation from 2000 to December 2018 were examined. Results: The survival rates at 1, 5, and 10 years on the waiting list were 98.4%, 90.3%, and 78.1%, respectively, while those after transplantation were significantly improved (p = 0.029) at 100%, 97.5%, and 88.9%, respectively. Furthermore, the survival rates of patients waiting for simultaneous pancreas and kidney transplantation (SPK) at 1, 5, and 10 years were 98.2%, 89.4%, and 75.4%, respectively, while those after SPK were also significantly improved (p = 0.026) at 100%, 94.6%, and 88.8%. The multivariable analysis revealed that the duration of diabetes before surgery was the only independent risk factor (hazard ratio = 1.095, p = 0.012) that affected the patient survival after SPK. Conclusion: Pancreas transplantation was found to improve the life prognosis of patients with type 1 diabetes, especially those with end-stage renal failure waiting for SPK.

11 May 2020 in Transplant International
Verified
Journal Article
Closed access
PDF file
TITAIHEI ITO
TAIHEI ITO
TKTakashi Kenmochi
Takashi Kenmochi
NANaohiro Aida
Naohiro Aida
KKKei Kurihara
Kei Kurihara
TATadafumi Asaoka
Tadafumi Asaoka
TIToshinori Ito
Toshinori Ito
Background In Japan, about 30% of pancreatic transplant donors are ≥50 years old, making them “extended criteria donors”. Methods We analyzed 361 cases of transplantation involving donors from the Japanese pancreas transplantation registry to evaluate the acceptability of extended criteria donors. Results The patient survival rates at 1, 5, and 10 years after transplantation were 96.6%, 94.9%, and 88.3%, respectively. The survival rates of pancreas and kidney grafts at 1, 5, and 10 years were 85.3%, 74.8%, 70.6% and 94.2%, 90.9%, and 80.9%, respectively. Multivariate analysis revealed that no particular donor factors significantly influenced the pancreatic graft survival. Patients were divided into 2 groups: donors ≥50 years old (older group) and those <50 years old (younger group). After propensity score matching, the overall pancreatic graft survival at 1, 5, and 10 years after transplantation in the older group was 82.8%, 71.8%, and 69.5%, respectively, which was almost the same as in the younger group (84.9%, 70.2%, and 67.4%, respectively). Conclusions No donor factors markedly influenced the pancreatic graft survival, and the outcomes of pancreas transplantation from extended criteria donors ≥50 years old were comparable to those from younger donors.

1 May 2018 in Pancreas
Verified
Journal Article
Closed access
NANaohiro Aida
Naohiro Aida
TKTakashi Kenmochi
Takashi Kenmochi
TITAIHEI ITO
TAIHEI ITO
TNToru Mt Nishikawa
Toru Mt Nishikawa
IHIzumi Hiratsuka
Izumi Hiratsuka
HMHisahiro Matsubara
Hisahiro Matsubara
Objectives: Contrast-enhanced ultrasonography can evaluate microcirculation. Thus, we used contrast-enhanced ultrasonography in evaluating pancreas graft perfusion and examined the relationship between graft circulation and function. Methods: Contrast-enhanced ultrasonography was performed in 17 cases within 24 hours and at 1, 3, 5, 7, 14, 21, and 28 days after transplantation (Tx). The time between the time to peak intensity in the parenchyma and that in the vein was defined as delta-Tp(P-V). Graft function was evaluated with oral glucose tolerance test (OGTT) at 1 and 3 months after Tx, and glucagon stimulation test at 1 month after Tx. Results: Differences in delta-Tp(P-V) between individual cases were more significant early after Tx, and delta-Tp(P-V) within 24 hours (delta-Tp[P-V]24h) was used in the subsequent analysis. Delta-Tp(P-V)24 hours showed a negative correlation with C-peptide increment in the glucagon stimulation test and the area under the curve of insulin level in oral glucose tolerance test. The cases were divided into the following 2 groups: the standard group (delta-Tp[P-V]24h ≤6.10 seconds) and the delayed group (>6.10 seconds). The area under the curve of insulin level increased significantly from 1 to 3 months after Tx in the standard group only. Conclusions: These results suggest that delta-Tp(P-V)24 hours affects insulin secretion after Tx. Contrast-enhanced ultrasonography is useful in predicting endocrine function of the graft.

30 November 2011 in Transplantation Proceedings
Verified
Journal Article
Closed access
KOK. Otsuki
K. Otsuki
KYK. Yoshikawa
K. Yoshikawa
TKTakashi Kenmochi
Takashi Kenmochi
MMM. Maruyama
M. Maruyama
NAN. Akutsu
N. Akutsu
TAT. Asano
T. Asano